[go: up one dir, main page]

PE20051156A1 - Formulaciones de matriz orales que comprenden licarbazepina - Google Patents

Formulaciones de matriz orales que comprenden licarbazepina

Info

Publication number
PE20051156A1
PE20051156A1 PE2005000316A PE2005000316A PE20051156A1 PE 20051156 A1 PE20051156 A1 PE 20051156A1 PE 2005000316 A PE2005000316 A PE 2005000316A PE 2005000316 A PE2005000316 A PE 2005000316A PE 20051156 A1 PE20051156 A1 PE 20051156A1
Authority
PE
Peru
Prior art keywords
hydrophilic
licarbazepine
formulations including
hydrophyl
matrix formulations
Prior art date
Application number
PE2005000316A
Other languages
English (en)
Inventor
Oskar Kalb
Marie-Christine Wolf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406379A external-priority patent/GB0406379D0/en
Priority claimed from GB0406738A external-priority patent/GB0406738D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20051156A1 publication Critical patent/PE20051156A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA ORAL DE LIBERACION CONTROLADA QUE COMPRENDE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ[b,f]AZEPIN-5-CARBOXAMIDA (LIACARZEPINA) Y UNA SUSTANCIA HIDROFILICA O LIPOFILICA HINCHABLE TAL COMO HIDROXIPROPILMETILCELULOSA ADECUADA PARA ADMINISTRARSE CADA DIA. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE PACIENTES CON DESORDENES AFECTIVOS
PE2005000316A 2004-03-22 2005-03-18 Formulaciones de matriz orales que comprenden licarbazepina PE20051156A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406379A GB0406379D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406738A GB0406738D0 (en) 2004-03-25 2004-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
PE20051156A1 true PE20051156A1 (es) 2006-02-13

Family

ID=34961345

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000316A PE20051156A1 (es) 2004-03-22 2005-03-18 Formulaciones de matriz orales que comprenden licarbazepina

Country Status (16)

Country Link
US (1) US20070196488A1 (es)
EP (1) EP1732519A1 (es)
JP (1) JP2007529564A (es)
AR (1) AR048318A1 (es)
AU (1) AU2005226910B2 (es)
BR (1) BRPI0509067A (es)
CA (1) CA2558787A1 (es)
EC (1) ECSP066860A (es)
IL (1) IL177826A0 (es)
MA (1) MA28527B1 (es)
MX (1) MXPA06010810A (es)
NO (1) NO20064808L (es)
PE (1) PE20051156A1 (es)
RU (1) RU2006137330A (es)
TW (1) TW200534844A (es)
WO (1) WO2005092294A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP2380573B1 (en) * 2005-05-06 2015-02-25 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
ES2687678T3 (es) 2011-03-08 2018-10-26 Jubilant Life Sciences Limited Procedimiento para la preparación de (S)-(+)-10,11-dihidro-10-hidroxi-5H-dibenzo[b,f]azepina-5-carboxamida y ésteres de la misma mediante reducción enantioselectiva de 10,11-dihidro-10-oxo-5H-dibenzo[b,f]azepina-5-carboxamida
EP2498481A1 (en) 2011-03-09 2012-09-12 Sensirion AG Mobile phone with humidity sensor
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
EP3957302A1 (en) 2015-12-18 2022-02-23 Jubilant Generics Limited Solid oral dosage forms of eslicarbazepine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
PL374778A1 (en) * 2002-05-31 2005-10-31 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
JP2005538126A (ja) * 2002-08-06 2005-12-15 ノバルティス アクチエンゲゼルシャフト 耳鳴の処置のためのカルボキサミドの使用
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina

Also Published As

Publication number Publication date
MXPA06010810A (es) 2006-12-15
WO2005092294A1 (en) 2005-10-06
EP1732519A1 (en) 2006-12-20
RU2006137330A (ru) 2008-05-10
TW200534844A (en) 2005-11-01
IL177826A0 (en) 2006-12-31
AU2005226910B2 (en) 2009-06-04
NO20064808L (no) 2006-12-15
MA28527B1 (fr) 2007-04-03
AR048318A1 (es) 2006-04-19
CA2558787A1 (en) 2005-10-06
JP2007529564A (ja) 2007-10-25
BRPI0509067A (pt) 2007-08-21
US20070196488A1 (en) 2007-08-23
AU2005226910A1 (en) 2005-10-06
ECSP066860A (es) 2006-11-24

Similar Documents

Publication Publication Date Title
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
GT199900203A (es) Composiciones de celecoxib.
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
CY1118179T1 (el) Φαρμακευτικη συνθεση
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
NO20065904L (no) Terapeutiske forbindelser
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PE20051156A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
AR056527A1 (es) Composicion farmaceutica para mejorar la funcion cognitiva
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
UA89753C2 (ru) Применение модафинила и антидепрессанта при лечении депрессии и для сокращения времени до начала действия антидепрессанта
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
PE20061051A1 (es) Composicion farmaceutica que comprende mirtazapina s
SE0203817D0 (sv) New composition
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
AR023763A1 (es) Agente que potencia la liberacion de acetilcolina en el cerebro

Legal Events

Date Code Title Description
FD Application declared void or lapsed